Share Price | Allarity Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is Allarity Therapeutics, Inc.?

Market Cap: As of Jun 18, Allarity Therapeutics, Inc. has a market capitalization of 12.46 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Allarity Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -23.40 million.Balance Sheet Snapshot: As of Dec 24, the company had shareholder's funds amounting to 11.81 million and total assets of 22.65 million.

Q: What does Allarity Therapeutics, Inc. do?

Overview: Allarity Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.Financial Snapshot: Net Profit: -3 Million (Quarterly Results - Mar 2025) Market Cap: USD 12.46 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.41 Return on Equity: -85.49% Price to Book: 0.67Contact Details: Details: No Company Details Available Registrar Address: Not available.

Q: Is Allarity Therapeutics, Inc. technically bullish or bearish?

As of 8 September 2025, the technical trend for Allarity Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD and Bollinger Bands indicate a mildly bullish stance, while the monthly MACD is also mildly bullish. The RSI shows a bearish signal on the weekly timeframe but is bullish on the monthly. Moving averages are bullish on the daily timeframe, and the KST is bullish weekly but bearish monthly. The Dow Theory suggests a mildly bullish stance on the weekly timeframe with no trend on the monthly. In terms of performance, the stock has underperformed the S&P 500 over the past week with a return of -15.05% compared to the S&P's 1.05%, but it has significantly outperformed over the past month with a return of 73.61% versus the S&P's 2.33%. Overall, the current technical stance is mildly bullish, driven by the mixed signals from the MACD, moving averages, and Dow Theory.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

202.09 k

Shareholding (Sep 2025)

FII

0.36%

Held by 4 FIIs

DII

97.43%

Held by 2 DIIs

Promoter

0.00%

How big is Allarity Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Allarity Therapeutics, Inc. has a market capitalization of 12.46 million, with net sales of 0.00 million and a net profit of -23.40 million over the last four quarters. The company reported shareholder's funds of 11.81 million and total assets of 22.65 million as of Dec 24.

View full answer

What does Allarity Therapeutics, Inc. do?

22-Jun-2025

Allarity Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $3 million and a market cap of $12.46 million. Key metrics include a negative P/E ratio, a 0.00% dividend yield, and a return on equity of -85.49%.

View full answer

Is Allarity Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Allarity Therapeutics, Inc. shows a mildly bullish trend with mixed technical indicators, having underperformed the S&P 500 recently but significantly outperformed it over the past month.

View full answer

Compare Allarity Therapeutics, Inc. with Similar Stocks

Galmed Pharmaceuticals Ltd.InMed Pharmaceuticals, Inc.Avalo Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 19 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.29

Return on Equity

-127.49%

Price to Book

1.58

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-34.15%

6 Months

-19.8%

1 Year

-23.22%

2 Years

-99.7%

3 Years

241.63%

4 Years

-100.0%

5 Years

0.0%

Allarity Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

8.75%

EBIT to Interest (avg)

-20.62

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.41

Sales to Capital Employed (avg)

Tax Ratio

1.48%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

9.10%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.68

EV to EBIT

0.83

EV to EBITDA

0.83

EV to Capital Employed

1.77

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

212.90%

ROE (Latest)

-85.49%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 2 Schemes (2.21%)

Foreign Institutions

Held by 4 Foreign Institutions (0.36%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -43.75% vs 33.33% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.10",
          "val2": "-3.40",
          "chgp": "-20.59%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.40",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "2.20",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.30",
          "val2": "-1.60",
          "chgp": "-43.75%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -105.88% vs 26.09% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-18.30",
          "val2": "-17.90",
          "chgp": "-2.23%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.70",
          "val2": "0.50",
          "chgp": "40.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-7.00",
          "val2": "5.70",
          "chgp": "-222.81%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-24.50",
          "val2": "-11.90",
          "chgp": "-105.88%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-4.10

-3.40

-20.59%

Interest

0.00

0.40

-100.00%

Exceptional Items

0.00

2.20

-100.00%

Consolidate Net Profit

-2.30

-1.60

-43.75%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -43.75% vs 33.33% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-18.30

-17.90

-2.23%

Interest

0.70

0.50

40.00%

Exceptional Items

-7.00

5.70

-222.81%

Consolidate Net Profit

-24.50

-11.90

-105.88%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -105.88% vs 26.09% in Dec 2023

All Annual Results

Company CV

About Allarity Therapeutics, Inc.

Allarity Therapeutics, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Allarity Therapeutics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Allarity Therapeutics, Inc.?

Watch in Real-Time

What does Allarity Therapeutics, Inc. do?

Is Allarity Therapeutics, Inc. technically bullish or bearish?

Compare Allarity Therapeutics, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Allarity Therapeutics, Inc.

Company Coordinates